Phosphatidylethanol vs Transdermal Alcohol Monitoring for Detecting Alcohol Consumption Among Adults.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
05 09 2023
Historique:
medline: 13 9 2023
pubmed: 12 9 2023
entrez: 12 9 2023
Statut: epublish

Résumé

Alcohol biomarkers can improve detection of heavy alcohol use in clinical care, yet cutoffs for phosphatidylethanol (PEth), a blood biomarker, have not been established. To determine the optimal cutoff for PEth for heavy alcohol consumption in a study of middle-age and older adults. This was a 4-week diagnostic study of adults with paroxysmal atrial fibrillation (AF) and current alcohol consumption, recruited from general cardiology and cardiac electrophysiology outpatient clinics from September 2014 to September 2019. Data were analyzed from October 2021 to March 2022. The main aim was to determine the optimal PEth cutoff for heavy alcohol consumption, using the Secure Continuous Remote Alcohol Monitor (SCRAM) to measure transdermal alcohol. Area under the curve (AUC) for PEth-detected compared with SCRAM-detected heavy alcohol consumption in any week over the prior 4 weeks (ie, ≥3 [women] and ≥4 [men] episodes) or any estimated breath alcohol of 0.08% or greater in any week, and the PEth cutoff was calculated using the Youden J statistic. Similar analyses were conducted comparing PEth with individual drinks reported by pressing an event monitor, retrospective self-report via the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), and using 2-week look-backs. In this diagnostic study of 64 patients with both PEth and SCRAM measures over 4 weeks (54 [84.4%] men; mean age, 65.5 [95% CI, 62.6-68.5] years; 51 [79.7%] White), 31 (48.4%) had any SCRAM-detected heavy alcohol consumption over the 4 weeks, and the median (IQR) PEth at 4 weeks was 23 ng/mL (<limit of quantification to 60 ng/mL). The AUC for PEth vs any SCRAM-detected heavy alcohol consumption was 0.83 (95% CI, 0.72-0.93). The optimal PEth cutoff was 18.5 ng/mL (AUC, 0.83; 95% CI, 0.72-0.93), with sensitivity of 83.9% (95% CI, 66.3%-94.5%) and specificity of 72.7% (95% CI, 54.5%-86.7%). The PEth test characteristics by individual drink reporting using the event monitors and by the AUDIT-C, and by these measures and by SCRAM collected for 2-week intervals, were similar to those compared with the 4-week SCRAM. In a predominately middle-age and older White male population, PEth compared well with SCRAM. A PEth cutoff of 18.5 ng/mL (or rounded to 20 ng/mL, a recommended PEth cutoff for significant alcohol consumption) can be used in clinical care to detect heavy alcohol consumption in middle-age and older men.

Identifiants

pubmed: 37698861
pii: 2809197
doi: 10.1001/jamanetworkopen.2023.33182
pmc: PMC10498325
doi:

Substances chimiques

phosphatidylethanol 0
Ethanol 3K9958V90M

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2333182

Subventions

Organisme : NIAAA NIH HHS
ID : K24 AA022586
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA022222
Pays : United States

Références

Alcohol Clin Exp Res. 2014 Jun;38(6):1706-11
pubmed: 24848614
Alcohol Clin Exp Res. 2007 Jul;31(7):1208-17
pubmed: 17451397
Alcohol Clin Exp Res. 2016 Jun;40(6):1228-34
pubmed: 27130527
Alcohol Clin Exp Res. 2012 Sep;36(9):1507-11
pubmed: 22458353
Ann Intern Med. 2021 Nov;174(11):1503-1509
pubmed: 34461028
Alcohol Clin Exp Res. 2010 Mar 1;34(3):488-92
pubmed: 20028353
J Forensic Sci. 2018 Nov;63(6):1634-1640
pubmed: 30005144
J Med Internet Res. 2022 Apr 14;24(4):e35178
pubmed: 35436239
Alcohol Clin Exp Res. 2021 Jun;45(6):1276-1286
pubmed: 33993541
MMWR Morb Mortal Wkly Rep. 2020 Oct 02;69(39):1428-1433
pubmed: 33001874
BMJ. 2015 Oct 28;351:h5527
pubmed: 26511519
Alcohol Clin Exp Res. 2021 Jun;45(6):1166-1187
pubmed: 33837975
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Alcohol Clin Exp Res. 2020 Dec;44(12):2449-2456
pubmed: 33038267
Alcohol Alcohol. 2006 Jul-Aug;41(4):431-7
pubmed: 16624837
Alcohol Alcohol. 2023 May 9;58(3):258-265
pubmed: 36928303
Alcohol Alcohol. 2006 May-Jun;41(3):306-10
pubmed: 16574672
Int J Legal Med. 2017 Jan;131(1):153-160
pubmed: 27596747
Biomolecules. 2015 Jun 29;5(3):1339-85
pubmed: 26131978
Drug Test Anal. 2022 Oct;14(10):1800-1802
pubmed: 35851997
Int J Mol Sci. 2012 Nov 13;13(11):14788-812
pubmed: 23203094
Exp Clin Psychopharmacol. 2014 Feb;22(1):86-96
pubmed: 24490713
Circulation. 2013 Dec 3;128(23):2470-7
pubmed: 24103419
Alcohol Clin Exp Res (Hoboken). 2023 Jan;47(1):7-17
pubmed: 36773022
Addict Biol. 2007 Mar;12(1):81-4
pubmed: 17407500
Alcohol Alcohol. 2004 Jul-Aug;39(4):325-8
pubmed: 15208165
Alcohol Alcohol. 2015 Jul;50(4):399-406
pubmed: 25882743
JAMA. 2018 Nov 13;320(18):1899-1909
pubmed: 30422199
Alcohol Res. 2016;38(1):115-20
pubmed: 27159818

Auteurs

Judith A Hahn (JA)

Department of Medicine, University of California, San Francisco.

Robin Fatch (R)

Department of Medicine, University of California, San Francisco.

Nancy P Barnett (NP)

Department of Behavioral and Social Sciences and the Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island.

Gregory M Marcus (GM)

Department of Medicine, University of California, San Francisco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH